Browsing Tag
transthyretin amyloidosis
1 post
Intellia’s Nexiguran Ziclumeran (nex-z) phase 3 trials paused following grade 4 liver toxicity event
Find out why Intellia Therapeutics paused its phase 3 Nexiguran Ziclumeran (nex-z) trials after a severe liver event—and what it means for CRISPR’s future.